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Prevalence of Vitamin D Insufﬁciency in Adult
Hematopoietic Cell Transplant (HCT) Patients with
Documented Osteopenia or Osteoporosis after Steroid
Exposure: A Quality Assurance Study
Erin M. Schmidt, Kerry K. McMillen. Nutrition, Seattle Cancer
Care Alliance, Seattle, WA
Background: Steroid exposure is a known risk factor for
osteopenia and osteoporosis. Vitamin D insufﬁciency is a
known factor that contributes to bone loss. Low concentra-
tions of vitamin D are associated with impaired calcium
absorption, negative calcium balance and a compensatory
rise in parathyroid hormone, which results in excessive bone
resorption. Historically at Seattle Cancer Care Alliance, adult
allogeneic HCT patients treated with steroids routinely have
a Dual Energy X-ray Absorptiometry (DEXA) scan at depar-
ture. While many patients were found to have osteopenia or
osteoporosis, it was unknown how many of these patients
were additionally vitamin D deﬁcient.
Objective: The aims of this quality assurance study were: 1)
to identify the prevalence of vitamin D insufﬁciency in adult
HCT patients with osteopenia or osteoporosis post-HCT and
2) to evaluate the need to change standard practice guide-
lines at our center to assess for vitamin D insufﬁciency more
regularly in at-risk groups.
Design: We identiﬁed all allogeneic HCT patients with post-
HCT steroid exposure and documented osteopenia or oste-
oporosis on departure DEXA scan over a six month period. A
serum 25-OH vitamin D level was drawn on patients meeting
these criteria.
Results: 40 adults met inclusion criteria: 22 males and 18
females. All patients were receiving 1500 mg calcium and
800 international units vitamin D3 daily with combination of
diet, multivitamin and/or supplements per standard practice
guidelines at Seattle Cancer Care Alliance. All patients were
counseled by a registered dietitian to ensure adequate cal-
cium and vitamin D intake.
4 patients had deﬁcient 25-OH vitamin D levels (25-OH
vitamin D <20 ng/mL), 25 patients had insufﬁcient levels
(25-OH vitamin D 20-30 ng/mL), 11 patients had normal
vitamin D levels (>30 ng/mL).
The prevalence of insufﬁciency or deﬁciency was 73% (29/
40). Stratiﬁed by age, the prevalence of insufﬁciency or
deﬁciency was:
20-29 years old 8% (3/40)
30-39 years old 10% (4/40)
40-49 years old 20% (8/40)
50-59 years old 15% (6/40)
60 years old 20% (8/40)
Males comprised 50% patients with 25-OH vitamin D
deﬁciency. 65% patients with 25-OH vitamin D insufﬁciency
were males, 35% females.
Conclusion/Applications: 25-OH vitamin D insufﬁciency
and deﬁciency are prevalent in post-HCT patients with
conﬁrmed osteopenia and/or osteoporosis. Vitamin D insuf-
ﬁciency and deﬁciency were prevalent across all ages and
genders highlighting the need to assess vitamin D status in
the total patient population.
Based on these ﬁndings, standard practice was modiﬁed
at Seattle Cancer Care Alliance to include a 25-OH vitamin D
level pre-HCT and at day 80 post-HCT to better identify and
treat 25-OH vitamin D insufﬁciency/deﬁciency.429
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Background: The prognosis of chronic myeloid leukemia
(CML) in advanced stages (accelerated phase or blast crisis) is
still poor even with tyrosine kinase inhibitors (TKIs). Allo-
geneic hematopoietic cell transplantation is the only curative
treatment for them.
Method: Using our database, we retrospectively collected
CML patients transplanted at Toranomon Hospital between
June 2004 and March 2014, after the introduction of TKIs in
Japan.
Result: Twenty-nine consecutive patients were extracted.
The median age was 52 years (range; 16-70). The disease
status at diagnosis was chronic phase (CP, n¼11), accelerated
phase (AP, n¼5) and blast crisis (BC, n¼13). All patients were
treated with TKIs before transplantation including imatinib
(n¼15), nilotinib (n¼1), dasatinib (n¼6), imatinib/dasatinib
(n¼4), nilotinib/dasatinib (n¼1) and imatinib/nilotinib/
dasatinib (n¼2). All of 11 patients in CP at diagnosis pro-
gressed into AP/BC in their course and only 3 patients ach-
ieved second CP at transplantation. On the other hand, 11 of
18 patients in AP/BC at diagnosis achieved CP at trans-
plantation and the remaining 7 patients did not achieve CHR
(Fig.1). The median HCT-CI and EBMT score at trans-
plantationwas 2 (range, 0-5) and 5 (range, 0-7), respectively.
Additional cytogenetic abnormalities developed in 19 of 29
patients until transplantation. Point mutations in ABL gene
were detected in 9 of 20 patients (45%) in their course.
Overall, 14 of 29 (48%) patients underwent transplantation in
CP stage. The donors were related PBSC (n¼6), unrelated BM
Figure 2. Overall survival (OS)
Figure 3. OS by disease status at transplantation
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S300(n¼4) or unrelated CB (n¼19). The conditioning regimens
were myeloablative in 20 patients and reduced-intensity in
9. Twenty-seven patients achieved neutrophil engraftment
at a median day of 19 (range, 10-34). The cumulative inci-
dence of neutrophil engraftment was 93.1% at day 42 (pa-
tients engrafted, n¼27; dead before day 19, n¼2). At 3 years,
the cumulative incidence of relapse and non-relapse mor-
tality was 32.3% and 14.0%, respectively. In 15 patients who
did not achieve CP before transplantation, 11 patients (73.3%)
achieved CR after transplantation. With a median follow-up
of survivors of 1144 days (range, 127-3705), overall survival
(OS) and event free survival (EFS) at 3 years was 63.2% and
56.3%, respectively. In univariate analysis, the variables that
inﬂuenced on OS were disease status at transplantation (CP
vs. AP/BC, 85% vs. 42%, p¼0.012), karyotype (sole Ph-chro-
mosome vs. additional cytogenetic abnormalities, 90% vs.
47.5%, p¼0.042) and conditioning regimen (MAC vs. RIC,
72.7% vs. 41.7%, p¼0.039). In multivariate analysis, the onlyvariable that inﬂuenced on OS was disease status at trans-
plantation (p¼0.015).
Conclusion: We concluded that allogeneic hematopoietic
cell transplantation from any cell sources could become a
promising option for the patients with CML in advanced
stage, especially if they achieved CP before transplantation.430
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Background: Matching for HLA-DPB1 lowers relapse risk in
allogeneic hematopoietic stem cell transplantation (ASCT),
but this locus is not in linkage disequilibrium with the
remainder of the HLA genes, makingmatchingmore difﬁcult.
Recent studies have suggested that after classifying HLA-
DPB1 mismatches based on T-cell epitope group, avoiding
non-permissive mismatches leads to improved survival. We
tested this hypothesis in our patient population.
Methods: We conducted a retrospective analysis of 78 pa-
tients who underwent ASCT at the Mayo Clinic 1/1/2008 -
12/21/2010. Patients with unrelated volunteer donors were
matched for HLA-A, B, C, DRB1 and DQB1 loci (10/10) at the
allele level without consideration of the HLA-DPB1 locus.
Patient and donor HLA-DPB1 genotyping was performed by
reverse SSO typing and the ImMunoGeneTics/HLA (IMGT/
HLA) T-cell epitope matching algorithm was used to deter-
mine mismatch status as permissive or non-permissive.
Results: Of 78 donor recipient pairs, therewere 13HLA-DPB1
matches, 42 permissive mismatches, and 23 non-permissive
mismatches (10 in the graft-vs-host [GvH] direction,13 in the
host-vs-graft [HvG] direction). In a univariate analysis, when
matches and permissive mismatches were combined into a
group and compared to non-permissive mismatch, therewas
no signiﬁcant difference in overall survival (p¼0.31), relapse
(p¼0.79), or neutrophil or platelet engraftment (p¼0.23 and
p¼0.99, respectively). No signiﬁcant difference was observed
in acute graft-vs-host disease (aGVHD; p¼0.25) or grade II-IV
aGVHD (p¼0.62) among the matched, permissive mis-
matched, and non-permissive mismatched groups. The
permissivemismatched group showed an increase in chronic
GVHD (cGVHD) over the matched and the non-permissive
mismatched groups that neared signiﬁcance (p¼0.052).
In univariate analyses, for non-permissive mismatches,
the GvH mismatch direction trended toward reduced sur-
vival (p¼0.26), increased relapse (p¼0.13), increased aGVHD
(p¼0.064), and increased cGVHD (p¼0.22).
Conclusions: We did not identify any signiﬁcant differ-
ences in survival, relapse, engraftment, or acute or chronic
GVHD among the patients with HLA-DPB1 donor matches,
permissive mismatches, and non-permissive mismatches,
although our study was limited by small sample size.
Further work from large databases is necessary to fully
understand the impact on clinical outcomes of HLA-DPB1
mismatches.
